

Martine Piccart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1949466/publications.pdf>

Version: 2024-02-01

105
papers

18,080
citations

61857

43
h-index

29081

104
g-index

106
all docs

106
docs citations

106
times ranked

19639
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1335-1345.	0.8	28
2	Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51.	1.3	8
3	Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 308-318.	1.1	2
4	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1117-1126.	3.0	3
5	Tolerability and toxicity of trastuzumab or trastuzumab+lapatinib in older patients: a sub-analysis of the ALTO trial (BIG 2-06; NCCTG (Alliance) N063D). <i>Breast Cancer Research and Treatment</i> , 2021, 185, 107-116.	1.1	2
6	Abstract PS12-17: Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome) Tj ETQq0 0 0 rgBT /Qverlock 10		
7	Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 38-47.	2.9	4
8	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488.	5.1	179
9	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	0.8	171
10	HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. <i>Cancers</i> , 2021, 13, 2824.	1.7	117
11	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
12	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5607-5618.	3.2	5
13	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , 2021, 99, 102229.	3.4	15
14	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235.	0.6	354
15	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	0.9	31
16	Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 462-470.	3.0	20
17	Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. <i>European Journal of Cancer</i> , 2020, 125, 69-82.	1.3	36
18	Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. <i>EBioMedicine</i> , 2020, 56, 102793.	2.7	22

#	ARTICLE	IF	CITATIONS
19	Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial. <i>Communications Biology</i> , 2020, 3, 397.	2.0	7
20	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	5.8	46
21	Management of early breast cancer in patients bearing germline BRCA mutations. <i>Seminars in Oncology</i> , 2020, 47, 243-248.	0.8	3
22	Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer. <i>Breast</i> , 2020, 52, 64-70.	0.9	8
23	Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 199-209.	1.1	19
24	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. <i>Clinical Cancer Research</i> , 2020, 26, 2783-2788.	3.2	27
25	Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1186-1197.	0.8	10
26	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1386.	1.8	33
27	Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 64.	2.3	20
28	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	3.0	73
29	PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?. <i>Npj Breast Cancer</i> , 2019, 5, 1.	2.3	55
30	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 103-114.	1.1	34
31	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFFECT). <i>European Journal of Cancer</i> , 2019, 114, 55-66.	1.3	30
32	Tumor dormancy at bedside: A late awakening. <i>Breast</i> , 2019, 45, 61-63.	0.9	8
33	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3887-3895.	3.2	42
34	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588.	3.2	73
35	Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review. <i>Current Treatment Options in Oncology</i> , 2019, 20, 37.	1.3	60
36	Systemic treatment of patients with early breast cancer: recent updates and state of the art. <i>Breast</i> , 2019, 48, S7-S20.	0.9	21

#	ARTICLE	IF	CITATIONS
37	Progress in adjuvant systemic therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 27-44.	12.5	175
38	Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast</i> , 2018, 39, 14-18.	0.9	14
39	Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2605-2615.	3.2	45
40	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). <i>Breast Cancer Research and Treatment</i> , 2018, 168, 631-638.	1.1	49
41	Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1115-1122.	3.0	49
42	Treatment of advanced HER2-positive breast cancer: 2018 and beyond. <i>Cancer Treatment Reviews</i> , 2018, 67, 10-20.	3.4	107
43	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138.	5.1	91
44	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. <i>Nature Communications</i> , 2017, 8, 14944.	5.8	126
45	The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data. <i>Clinical Cancer Research</i> , 2017, 23, 2702-2712.	3.2	82
46	Recurrence dynamics of breast cancer according to baseline body mass index. <i>European Journal of Cancer</i> , 2017, 87, 10-20.	1.3	35
47	The AURORA pilot study for molecular screening of patients with advanced breast cancer—a study of the breast international group. <i>Npj Breast Cancer</i> , 2017, 3, 23.	2.3	8
48	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 122-131.	13.9	1,033
49	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	3.4	118
50	Unusual presentation of nasopharyngeal carcinoma with rectal metastasis. <i>World Journal of Clinical Cases</i> , 2017, 5, 183.	0.3	4
51	Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. <i>PLoS ONE</i> , 2017, 12, e0172351.	1.1	10
52	Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer. <i>World Journal of Clinical Oncology</i> , 2017, 8, 425-428.	0.9	5
53	Cancer drugs, survival and ethics: a critical look from the inside. <i>ESMO Open</i> , 2016, 1, esmoopen-2016-000149.	2.0	4
54	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	3.0	24

#	ARTICLE	IF	CITATIONS
55	Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 811-821.	5.1	239
56	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729.	13.9	1,427
57	Endocrine treatment in breast cancer: Cure, resistance and beyond. <i>Cancer Treatment Reviews</i> , 2016, 50, 68-81.	3.4	114
58	Targeted adjuvant therapy in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1263-1275.	1.1	11
59	Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist. <i>Journal of Geriatric Oncology</i> , 2016, 7, 463-470.	0.5	43
60	Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. <i>European Journal of Cancer</i> , 2016, 63, 97-104.	1.3	44
61	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 127-132.	1.1	7
62	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. <i>JAMA Oncology</i> , 2016, 2, 217.	3.4	21
63	A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). <i>European Journal of Cancer</i> , 2016, 53, 144-154.	1.3	29
64	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	0.8	203
65	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0154009.	1.1	27
66	Uncovering the genomic heterogeneity of multifocal breast cancer. <i>Journal of Pathology</i> , 2015, 236, 457-466.	2.1	72
67	The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0138341.	1.1	16
68	Final 10-year results of the Breast International Group 98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489.	1.3	32
69	Clinical management of breast cancer heterogeneity. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 381-394.	12.5	400
70	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. <i>BMC Medicine</i> , 2015, 13, 177.	2.3	45
71	Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. <i>Cell Reports</i> , 2015, 13, 277-289.	2.9	179
72	Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015. <i>Breast</i> , 2015, 24, S143-S148.	0.9	18

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant Therapy for Breast Cancer. Annual Review of Medicine, 2015, 66, 31-48.	5.0	55
74	An update on PARP inhibitors moving to the adjuvant setting. Nature Reviews Clinical Oncology, 2015, 12, 27-41.	12.5	316
75	New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors. Clinical Cancer Research, 2014, 20, 6242-6246.	3.2	15
76	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, The, 2014, 384, 164-172.	6.3	3,224
77	An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case. European Journal of Cancer, 2014, 50, 3089-3097.	1.3	13
78	Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. Journal of Clinical Oncology, 2014, 32, 2794-2803.	0.8	298
79	Biology of breast cancer during pregnancy using genomic profiling. Endocrine-Related Cancer, 2014, 21, 545-554.	1.6	58
80	Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. Cancer Treatment Reviews, 2014, 40, 1089-1095.	3.4	30
81	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. Breast, 2014, 23, 473-481.	0.9	11
82	Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer, 2013, 13, 190.	1.1	11
83	Personalized therapy for breast cancer: a dream or a reality?. Future Oncology, 2013, 9, 1105-1119.	1.1	27
84	¹⁸ F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. Journal of Nuclear Medicine, 2013, 54, 1862-1868.	2.8	132
85	Personalized medicine for breast cancer: dream or reality?. Memo - Magazine of European Medical Oncology, 2013, 6, 158-166.	0.3	0
86	Emerging targeted agents in metastatic breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 191-210.	12.5	158
87	Beyond Trastuzumab and Lapatinib: New Options for HER2-Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e2-e11.	1.8	16
88	Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment. Clinical Cancer Research, 2012, 18, 1004-1014.	3.2	46
89	Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis. Journal of Clinical Oncology, 2012, 30, 1996-2004.	0.8	194
90	Everolimus in Postmenopausal Hormone-Receptor Positive Advanced Breast Cancer. New England Journal of Medicine, 2012, 366, 520-529.	13.9	2,474

#	ARTICLE	IF	CITATIONS
91	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 527-539.	5.1	116
92	HER-2 as a Target for Breast Cancer Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 1848-1852.	3.2	36
93	Novel therapeutics in breast cancer—Looking to the future. <i>Update on Cancer Therapeutics</i> , 2009, 3, 189-205.	0.9	7
94	Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, S100-S113.	1.1	37
95	Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. <i>Breast Cancer Research</i> , 2008, 10, R65.	2.2	765
96	The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. <i>European Journal of Cancer</i> , 2008, 44, 84-91.	1.3	145
97	Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. <i>Clinical Cancer Research</i> , 2008, 14, 5158-5165.	3.2	745
98	Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor—Positive, Advanced Breast Cancer: Results From EFACT. <i>Journal of Clinical Oncology</i> , 2008, 26, 1664-1670.	0.8	460
99	First-Line Treatment of Metastatic Breast Cancer. <i>American Journal of Cancer</i> , 2006, 5, 99-110.	0.4	11
100	Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 262-272.	3.0	1,824
101	Use of trastuzumab for the treatment of early stage breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1153-1164.	1.1	13
102	Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 540-551.	4.3	222
103	Trastuzumab and Breast Cancer. Are we just Beyond the Prologue of a Fascinating Story?. <i>Oncology Research and Treatment</i> , 2005, 28, 547-549.	0.8	6
104	New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 53-60.	1.1	15
105	The Role of Taxanes in the Adjuvant Treatment of Early Stage Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 79, 25-34.	1.1	47